3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile

Identification

Generic Name
3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile
DrugBank Accession Number
DB08444
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 420.262
Monoisotopic: 419.038172742
Chemical Formula
C20H14BrN5O
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UGag-Pol polyproteinNot Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as bromodiphenyl ethers. These are compounds that contain two benzene groups linked to each other via an ether bond, and where at least one ring is substituted with a bromo group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Bromodiphenyl ethers
Alternative Parents
Diarylethers / Pyrazolopyridines / Phenoxy compounds / Phenol ethers / Benzonitriles / Toluenes / Bromobenzenes / Pyridines and derivatives / Pyridazines and derivatives / Aryl bromides
show 7 more
Substituents
Aromatic heteropolycyclic compound / Aryl bromide / Aryl halide / Azacycle / Azole / Benzonitrile / Bromobenzene / Bromodiphenyl ether / Carbonitrile / Diaryl ether
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
YYGZQXRLQMFHDH-UHFFFAOYSA-N
InChI
InChI=1S/C20H14BrN5O/c1-12-6-14(11-22)8-15(7-12)27-19-3-2-13(9-17(19)21)10-18-16-4-5-23-25-20(16)26-24-18/h2-9H,10H2,1H3,(H,24,25,26)
IUPAC Name
3-[2-bromo-4-({1H-pyrazolo[3,4-c]pyridazin-3-yl}methyl)phenoxy]-5-methylbenzonitrile
SMILES
CC1=CC(=CC(OC2=C(Br)C=C(CC3=NNC4=NN=CC=C34)C=C2)=C1)C#N

References

General References
Not Available
PubChem Compound
25058138
PubChem Substance
99444915
ChemSpider
24690847
BindingDB
27618
ChEMBL
CHEMBL459170
ZINC
ZINC000040864726
PDBe Ligand
PZ2
PDB Entries
3e01

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00666 mg/mLALOGPS
logP4.39ALOGPS
logP4.07Chemaxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.27Chemaxon
pKa (Strongest Basic)1.86Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area87.48 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity107.67 m3·mol-1Chemaxon
Polarizability38.07 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9737
Caco-2 permeable-0.5557
P-glycoprotein substrateNon-substrate0.5284
P-glycoprotein inhibitor INon-inhibitor0.6575
P-glycoprotein inhibitor IINon-inhibitor0.7171
Renal organic cation transporterNon-inhibitor0.5547
CYP450 2C9 substrateNon-substrate0.7944
CYP450 2D6 substrateNon-substrate0.794
CYP450 3A4 substrateSubstrate0.5432
CYP450 1A2 substrateInhibitor0.8536
CYP450 2C9 inhibitorInhibitor0.6088
CYP450 2D6 inhibitorNon-inhibitor0.7327
CYP450 2C19 inhibitorInhibitor0.6741
CYP450 3A4 inhibitorInhibitor0.9547
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9212
Ames testNon AMES toxic0.5052
CarcinogenicityNon-carcinogens0.9241
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6254 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5698
hERG inhibition (predictor II)Non-inhibitor0.7964
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0100900000-c2483a1671c6d7ff8352
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0000900000-7fddd399f55cd6cda884
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fdo-0208900000-898db66e15b92909a114
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0159-1405900000-2b9a5b5068f12701d294
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0126900000-12972ced6ea692ae6cf3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00lr-9400000000-6f90a6d619860d637a9c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-182.67754
predicted
DeepCCS 1.0 (2019)
[M+H]+185.03554
predicted
DeepCCS 1.0 (2019)
[M+Na]+191.80269
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Not Available
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spher...
Gene Name
gag-pol
Uniprot ID
P04585
Uniprot Name
Gag-Pol polyprotein
Molecular Weight
162041.05 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at September 15, 2010 21:31 / Updated at June 12, 2020 16:52